Disclosure of Clinical Trial Results When Product Development Is Abandoned

Science Translational Medicine  28 Sep 2011:
Vol. 3, Issue 102, pp. 102cm29
DOI: 10.1126/scitranslmed.3002939

You are currently viewing the abstract.

View Full Text


Currently, sponsors are not required to report the outcomes of clinical research on drugs or devices that do not lead to an approved product. Consequently, the public cannot benefit from scientific information derived from all failed or abandoned drugs and devices. Provisions in the U.S. Food and Drug Administration Amendments Act of 2007 provide an opportunity for the Department of Health and Human Services to rectify this situation. By reporting the results of clinical trials of abandoned products in a publicly accessible database and in the peer-reviewed journal literature, sponsors would satisfy a core ethical obligation of clinical research and enhance translational science.

View Full Text